Cross-border biotech Anji Pharma closed $70 million in Series B funding to advance a drug pipeline that includes metabolic and cancer drugs. The biotech’s business model of finding promising drugs and forming subsidiaries to develop them is similar to approaches taken by Roivant Sciences and BridgeBio Pharma, among others.
The list of FDA-approved antibody drug conjugates (ADC) is growing, and two more biotech startups have emerged from stealth with new cash and new approaches to this type of cancer drug. Adcendo and Adcentrx raised a combined $112 from their Series A financings.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The designation, for the PD-1 inhibitor toripalimab in nasopharyngeal carcinoma, makes the Shanghai-based company the latest of several Chinese biotech firms to make headway in the U.S. market.
Veteran international healthcare entrepreneur Semih Sen will also oversee Cleveland Clinic Innovations, the commercialization arm of the organization, which is focused on bringing research IP into the market.
Some Chinese attendees said they are not yet affected but maybe while others said they weren't affected and that the trade impasse was likely to turn the attention of the biotech companies to Europe. Chinese pharma wouldn't be affected.
Exuma Biotechnology will expand its program to multiple centers in China this summer and decide whether to expand to the US or Europe by the end of the year, the company's founder said. It has also developed its own electronic system for ensuring chain of custody for its products.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
There was $43 billion raised for new venture capital and private equity funds targeting China life science investments in 2018, with the average fund size increasing to $765 million.
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
The deal will bring the CAR-T therapy to China's burgeoning market, but it faces competition from Gilead's Yescarta - manufactured under a JV with Fosun - and also homegrown products.
The company has been busy forming development and commercialization partnerships with other firms to develop antibodies in oncology and rheumatology.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Investors, including Ali Baba billionaire Jack Ma, have cut a fresh check for WuXi NextCODE to the tune of $75 million. The Shanghai-based genomics specialist has a wide range of international services and new consumer products for the Chinese market.
Deregulation, health insurance reform, an aging senior population, and the need to improve access to care, coupled with the rise in smartphone ownership are factors fueling digital health's growth in this Asian nation.
The entrepreneurial café culture is a growing phenomenon in China. Café 1898 is franchising in other Chinese cities and plans to launch a branch in California.
The cross-border investment firm now has $350 million under management. It's invested in some high profile biopharma companies - including Juno Therapeutics, Foundation Medicine and Novira Therapeutics.